Cervical Cancer

Screening Portfolio

Evolving methods, one goal: the prevention of cervical cancer


Cervical cancer: the 4th most frequent cancer in women1

While preventable, cervical cancer takes a heavy toll1. The high mortality rate from cervical cancer globally could be reduced through a comprehensive approach that includes prevention, early diagnosis, effective screening and treatment programs.1


women diagnosed worldwide per year1


deaths worldwide per year1


BD offers assays and instruments to support the cervical cancer screening needs of today and tomorrow.

The added complexity due to the HPV vaccination, in conjunction with the variability of screening methods, underscores the importance of a medical technology partner fully able to support and adapt to the requirements of healthcare providers and laboratories.

Cytology primary Cytology primary
HPV primary HPV primary
Co-testing Co-testing

Cytology primary with ASCUS reflex

The BD SurePath™ Liquid-based Pap Test provides:

  • An FDA approved solution for primary cytology screening
  • Higher HSIL+ detection and lower unsatisfactory rate compared to conventional cytology and the ThinPrep® Pap Test2
  • 100% of collected sample sent to the laboratory for testing4

The BD Onclarity™ HPV Assay provides:

  • An HPV testing solution for ASCUS reflex

HPV Primary

The BD Onclarity™ HPV Assay provides:

  • DNA-based PCR assay with proven and validated performance3
  • Internal cellularity control to minimize false-negative results
  • Enhanced genotyping to allow risk stratification and reduce unnecessary colposcopies

The BD SurePath™ Liquid-based Pap Test provides:

  • An FDA approved collection vial for HPV primary screening


The BD SurePath™ Collection Vial provides an FDA approved single source vial for cytology and HPV co-testing with the BD SurePath™ Liquid-based Pap Test and the BD Onclarity™ HPV Assay

Contact us to discuss how we can support your cervical cancer screening needs.

Contact us

  1. World Health Organization. Cervical Cancer. Available at: Assessed on September 25, 2019.
  2. Nance KV. Diagn Cytopathol. 2007; 35:148-153.
  3. BD Onclarity HPV Assay [US Package Insert 8089894] Sparks, MD: Becton, Dickinson and Company, 2020.
  4. BD Surepath Collection Vial [US Package Insert 500017013] Sparks, MD: Becton, Dickinson and Company, 2020.

Contact Us